A 46-year-old man with type I Brugada syndrome and hypertension.
Recently, she had switched her medication to 80 mg ixekizumab, after secondary ineffectiveness of 45 mg ustekinumab for moderate or severe chronic plaque psoriasis.
One week after the first dose of ixekizumab, the patient developed fever and‚ñÅmalaise.
A nasopharyngeal swab was positive for SARS-CoV-2.
After 4 days from the onset of symptoms, the patient came to the emergency department with dyspnea and chest pain.
Oxygen saturation was 90%; chest ultrasound was consistent with bilateral interstitial pneumonia; chest X-ray showed no pulmonary opacities or pleural effusion.
The patient was hospitalized and treated with 400 mg of hydroxychloroquine twice daily orally on the first day, followed by 200 mg twice daily, 1 g of ceftriaxone twice daily non-invasive mechanical ventilation in non-invasive decubitus.
Antivirals were not given because of the risk of arrhythmia.
Fever resolved after 14 days, which allowed passage from CPP to low flow therapy.
The patient was discharged after 22 days, with oxygen saturation of 97% on the walking test.
Two nasopharyngeal swabs repeated for SARS-CoV-2 were negative 30 days after diagnosis.
